nach oben

12.04.2015 | Fortbildung | Ausgabe 4/2015

Keimzelltumoren des Hodens

Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren

Zeitschrift:: Uro-News > Ausgabe 4/2015

Autor:: Prof. Dr. med. Arthur Gerl

Keimzelltumoren des Hodens sind zwar selten, doch meistens sind es junge Männer, die betroffen sind. Die Behandlungsaussichten der Patienten sind allerdings gut, wenn sie stadienadaptiert behandelt und auch nach der Therapie intensiv weiter betreut werden.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Bosl GJ et al. Testicular germ-cell cancer. N Engl J Med. 1997; 337:242–254. CrossRefPubMed

Gerl A et al. Advances in the management of metastatic non-seminomatous germ-cell tumours: a single institution experience. Br J Cancer. 1996;74:1280–1285. CrossRefPubMedCentralPubMed

Horwich A. Testicular germ cell tumours. Br Med J. 2013; 347:5526–5534. CrossRef

Cullen MH et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol. 1996;14:1106–1113. PubMed

Albers P et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous germ cell tumors. AUO trial AH 01/94 by the German Testicular Germ Cell Cancer Study Group. J Clin Oncol. 2008;28:2966–2972. CrossRef

Nichols CR et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol. 2013;31:3490–3493. CrossRefPubMed

Cathomas R et al. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie. 2011;34:59–64. CrossRefPubMed

Stephenson AJ et al. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous testicular germ cell cancer. J Clin Oncol. 2007;35:5597–5602. CrossRef

International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor based staging system for metastatic germ cell tumors. J Clin Oncol. 1997;15:594–603.

10.

Saxman SB et al. Long-term follow-up of a phase III study of three versus four cyles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indiana University experience. J Clin Oncol. 1998;16:702–706. PubMed

11.

de Wit R et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Cancer Collaborative Group and the Medical Research Council. J Clin Oncol. 2001;19:629–640.

12.

Toner GC et al. for the Australian and New Zealand Germ Cell Trial Group. Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Lancet 2001;357:739–745. CrossRefPubMed

13.

de Wit R et al. Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin to standard BEP in intermediate prognosis germ cell-cancer. Intergroup Study EORTC 30983. J Clin Oncol. 2012;30:792–799. CrossRefPubMedCentralPubMed

14.

Motzer RJ et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poorprognosis metastatic germ cell tumors. J Clin Oncol. 2007;25:247–256. CrossRefPubMed

15.

Schmoll HJ et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol. 2003;21:4083–4091. CrossRefPubMed

16.

Fizazi K et al. Phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors. Results of GETUG 13. J Clin Oncol. 2013; 31 (suppl; abstr LBA4500).

17.

Albany C et al. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1-antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day ciplatin combination chemotherapy regimens: a Hoosier Oncology Group Study. J Clin Oncol. 2012;30:3998–4003. CrossRefPubMed

18.

Basch E et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189–4198. CrossRefPubMed

19.

Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006;24:3187–3205. CrossRefPubMed

20.

Gerl A et al. Outcome analysis after postchemotherapy surgery in patients with non-seminomatous germ cell tumours. Ann Oncol. 1995;6:483–488. PubMed

21.

Steyerberg EW et al. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol. 1998;16:269–274. PubMed

22.

Debono DJ et al. Decision analysis for avoiding postchemotherapy surgery in patients with disseminated nonseminomatous gem cell tumors. J Clin Oncol. 1997;15:1455–1464. PubMed

23.

Steyerberg EW et al. Residual masses after chemotherapy for metastatic testicular cancer: the clinical implications of the association between retroperitoneal and pulmonary histology. J Urol. 1997;158:474–478. CrossRefPubMed

24.

Fizazi K et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy — results from an international study group. J Clin Oncol. 2001;19:2647–2657. PubMed

25.

Warde P et al. Prognostic factors for relapse in stage I seminoma managed by surveillance. J Clin Oncol. 2002; 20:4448–4452. CrossRefPubMed

26.

Beard CJ et al. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer. 2013;119:2771–2777. CrossRefPubMed

27.

Mead GM et al. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst. 2011;103:241–249. CrossRefPubMed

28.

Gerl A et al. Can Abdominal Ultrasound Replace CT Scanning in Long-Term Follow-up of Male Patients with Germ Cell Tumor? J Clin Oncol. 2012;30(15S):302s.

29.

Fossa SD et al. Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. Eur J Cancer. 1997;33:1380–1387. CrossRefPubMed

30.

Bokemeyer C et al. Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomized trials. Br J Cancer. 2004;91:683–687. PubMedCentralPubMed

31.

De Santis M et al. 2–18fluorodeoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update from the multicenter SEMPET trial. J Clin Oncol. 2004;22:1034–1039. CrossRefPubMed

32.

Einhorn LH et al. High-dose chemotherapy and stem cell rescue in metastatic germ cell tumors. N Engl J Med. 2007;357:140–148. CrossRef

33.

Lorch A et al. Conventional versus highdose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011;29:2178–2184. CrossRefPubMed

34.

Lorch A et al. Sequential versus single highdose chemotherapy in relapsed or refractory germ cell tumors: long-term results of a prospective randomized trial. J Clin Oncol. 2012;30:800–805. CrossRefPubMed

35.

International Prognostic Factor Study Group. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatinbased first-line chemotherapy. J Clin Oncol. 2008;28:4906–4911. CrossRef

36.

Oechsle K et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol. 2011;60:850–855. CrossRefPubMed

37.

Gerl A et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol. 1997;8:41–47. CrossRefPubMed

38.

Gerl A et al. The impact of chemotherapy on Leydig cell function in long-term survivors with germ cell tumors. Cancer. 2001;91:1297–1303. CrossRefPubMed

39.

Fegg MJ et al. Subjective quality of life and sexual functioning after germ cell tumour therapy. Br J Cancer. 2003;89:2202–2206. CrossRefPubMedCentralPubMed

40.

Travis JB et al. Testicular cancer survivorship. Research strategies and recommendations. J Natl Cancer Inst. 2010;102:1114–1130. CrossRefPubMedCentralPubMed

Titel: Keimzelltumoren des Hodens
Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren
Autor:: Prof. Dr. med. Arthur Gerl
Publikationsdatum: 12.04.2015
DOI: https://doi.org/10.1007/s00092-015-0592-6
Verlag: Urban & Vogel
Zeitschrift: Uro-News
Ausgabe 4/2015
Print ISSN: 1432-9026
Elektronische ISSN: 2196-5676

Neu im Fachgebiet Urologie

27.02.2021 | Risikofaktoren für Krebserkrankungen | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

Aktuelle Therapie- und Nachsorgestrategien bei Hodentumoren

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Urologie

Sinkende Karzinogenexposition – aber immer noch steigende Krebsraten

Active Surveillance bei Prostata-Ca.: Ist mehr Vorsicht angebracht?

Krebsmortalität sinkt europaweit – mit Ausnahmen

Urolithiasis: Mehr komplizierte Verläufe bei Frauen

Newsletter

Springer Medizin

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Risikofaktoren der Brushit-Steinbildung

Studienleitung haut niedergelassene Urologen öffentlich in die Pfanne

Ein kritischer Blick auf Steindiäten

Noch drängen Patienten nicht auf die ärztliche Zweitmeinung

Niedrige PSA-Werte? Dann reicht ein PSA-Check alle 10 Jahre

Individualisierte Therapie bei Keimzelltumoren mit schlechter Prognose

Neu im Fachgebiet Urologie

Sinkende Karzinogenexposition – aber immer noch steigende Krebsraten

Active Surveillance bei Prostata-Ca.: Ist mehr Vorsicht angebracht?

Krebsmortalität sinkt europaweit – mit Ausnahmen

Urolithiasis: Mehr komplizierte Verläufe bei Frauen

Newsletter